EVOLUTION-HF DE_allEF: A non-interventional study of patients with heart failure initiated on dapagliflozin: study design.

ABSTRACT:

Aims

Heart failure (HF) is one of today's leading public health issues worldwide. The sodium-glucose cotransporter 2 inhibitor (SGLT2i) dapagliflozin recently received a label expansion. It is now approved for treatment of HF across the entire spectrum of ejection fraction (EF) in Germany. However, real-world data are limited. EVOLUTION-HF DE_allEF aims to complement existing data in Germany under the multinational umbrella EVOLUTION-HF study protocol.

Methods

EVOLUTION-HF DE_allEF (NCT06336330) is a non-interventional, prospective, longitudinal cohort study. It is planned to enrol a total of 1000 (700 evaluable) patients with HF in Germany. Distribution is planned as 40% patients with preserved (HFpEF), 20% with mildly reduced (HFmrEF), and 40% with redu

SUBMITTER: Paul M 

PROVIDER: S-EPMC12287773 | biostudies-literature | 2025 Aug

REPOSITORIES: biostudies-literature